Anatara Lifesciences Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anatara Lifesciences yıllık ortalama 11.4% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 13.2% annual. Gelirler azalıyor .

Anahtar bilgiler

11.4%

Kazanç büyüme oranı

28.6%

EPS büyüme oranı

Biotechs Sektör Büyümesi	9.6%
Gelir büyüme oranı	-64.1%
Özkaynak getirisi	-106.4%
Net Marj	n/a
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Anatara Lifesciences nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

CHIA:ANR Gelir, gider ve kazançlar (AUD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Jun 24	0	-1	1
31 Mar 24	0	-2	1
31 Dec 23	0	-2	1
30 Sep 23	0	-2	2
30 Jun 23	0	-2	2
31 Mar 23	0	-2	2
31 Dec 22	0	-2	2
30 Sep 22	0	-2	2
30 Jun 22	0	-3	2
31 Mar 22	0	-2	2
31 Dec 21	0	-2	2
30 Sep 21	0	-2	2
30 Jun 21	0	-2	2
31 Mar 21	0	-2	2
31 Dec 20	0	-3	3
30 Sep 20	0	-3	3
30 Jun 20	0	-3	3
31 Mar 20	0	-3	3
31 Dec 19	1	-3	3
30 Sep 19	1	-3	3
30 Jun 19	1	-3	4
31 Mar 19	0	-3	4
31 Dec 18	0	-4	5
30 Sep 18	0	-4	5
30 Jun 18	0	-4	4
31 Mar 18	1	-3	4
31 Dec 17	2	-3	4
30 Sep 17	2	-2	3
30 Jun 17	3	-2	3
31 Mar 17	4	-1	3
31 Dec 16	4	0	3
30 Sep 16	3	0	3
30 Jun 16	2	-1	2
31 Mar 16	1	-1	2
31 Dec 15	0	-2	2
30 Sep 15	0	-2	2
30 Jun 15	0	-2	2
31 Mar 15	0	-2	1
31 Dec 14	0	-2	1
30 Sep 14	0	-1	1
30 Jun 14	0	-1	1

Kaliteli Kazançlar: ANR şu anda kârlı değil.

Büyüyen Kar Marjı: ANR şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: ANR kârlı değildir, ancak son 5 yılda zararlarını yılda 11.4% oranında azaltmıştır.

Büyüme Hızlandırma: ANR 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: ANR kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 4% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: ANR hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -106.35% ) sahiptir.

Anatara Lifesciences Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

First half 2021 earnings released: AU$0.016 loss per share (vs AU$0.036 loss in 1H 2020)

Recent updates

Anatara Lifesciences Ltd has completed a Follow-on Equity Offering in the amount of AUD 0.75 million.

Anatara Lifesciences Ltd has filed a Follow-on Equity Offering in the amount of AUD 0.5 million.

Anatara Lifesciences Ltd, Annual General Meeting, Nov 14, 2024

Anatara Lifesciences Ltd has completed a Follow-on Equity Offering in the amount of AUD 1 million.

Anatara Lifesciences Ltd has filed a Follow-on Equity Offering in the amount of AUD 1 million.

No independent directors

New major risk - Shareholder dilution

Anatara Lifesciences Ltd has completed a Follow-on Equity Offering in the amount of AUD 1.315185 million.

New major risk - Shareholder dilution

No independent directors

Anatara Lifesciences Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.055331 million.

Anatara Lifesciences Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.055331 million.

No independent directors

Less than half of directors are independent

Anatara Lifesciences Ltd, Annual General Meeting, Nov 10, 2023

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Anatara Lifesciences Ltd Announces board Changes

Insufficient new directors

Insufficient new directors

Anatara Lifesciences Limited, Annual General Meeting, Nov 11, 2022

Anatara Lifesciences Limited Provides Updates on 3FDC Clinical Trial

Insufficient new directors

Anatara Lifesciences Limited Appoints John Michailidis as Chief Operations Officer

Insufficient new directors

Anatara Lifesciences Updates on Progress of Clinical Trials in Psychological Functioning and Irritable Bowel Syndrome, Diarrhoea Subtype

Insufficient new directors

Anatara Lifesciences Provides Clinical Trials Update

Insufficient new directors

Insufficient new directors

Anatara Lifesciences Limited Provides Clinical Trials Update on Progress of Clinical Trials in Psychological Functioning and Irritable Bowel Syndrome, Diarrhoea Subtype

Insufficient new directors

High number of new directors

Anatara Lifesciences Limited Provides Update on Progress of Clinical Trials in Psychological Functioning and Irritable Bowel Syndrome

Anatara Lifesciences Provides This Update on Clinical Trial Activities

Insider recently sold AU$177k worth of stock

First half 2021 earnings released: AU$0.016 loss per share (vs AU$0.036 loss in 1H 2020)

Anatara Lifesciences Receives Ethics Approval to Start IBS Trial

Anatara Lifesciences Announces Successful Poultry Trial

New 90-day high: AU$0.22

Anatara Lifesciences Limited Announces Cessation of Tracie Elizabeth Ramsdale as Director

Anatara Lifesciences Limited Announces Retirement of Tracie Ramsdale as Non-Executive Director

Anatara Lifesciences Limited Auditor Raises 'Going Concern' Doubt

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin